

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

FORM 8-K/A

CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **January 4, 2008**

ACCESS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State or other jurisdiction of incorporation)	<u>0-9314</u> (Commission File Number)	<u>83-0221517</u> (IRS Employer Identification No.)
<u>2600 Stemmons Freeway, Suite 176 Dallas, Texas</u>		<u>75207</u>
(Address of principal executive offices)		(Zip Code)
Registrant's telephone number, including area code:		<u>(214) 905-5100</u>

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- // Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- // Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- // Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- // Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Access Pharmaceuticals, Inc (“Access”) filed a Current Report on Form 8-K with the Securities and Exchange Commission on January 9, 2008 (the “Initial Filing”), relating to the entry into and the completion of Access’ acquisition of Somanta Pharmaceuticals, Inc. (“Somanta”), Somanta Incorporated, a Delaware corporation and a wholly owned subsidiary of Somanta and Somanta Limited, a company organized under the laws of England and a wholly-owned subsidiary of Somanta.

This Amendment No. 1 to the Initial Filing on Form 8-K/A is being filed solely to amend and restate Item 9.01 of the Initial Filing to include Somanta’s financial statements and pro forma financial information required by Item 9.01 of Form 8-K. The registrant has amended and restated the Initial Filing for the inclusion of the foregoing financial statements and pro forma financial statements. Except as set forth above, no other changes are being made to the Initial Filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(a) Financial Statements of Business Acquired

Somanta Pharmaceuticals, Inc. audited consolidated financial statements are hereby incorporated by reference. The statements were audited by Stonefield Josephson, Inc.

(b) Pro Forma Financial Information

The following unaudited pro forma condensed combined financial statements apply to the merger between Somanta and Access, by which Somanta became a wholly owned subsidiary of Access, and are based upon the historical condensed consolidated financial statements and notes thereto (as applicable) of Access and Somanta, which are incorporated by reference into this Form 8K/A. The unaudited pro forma condensed combined balance sheet gives pro forma effect to the merger as if the merger had been completed on December 31, 2007 and combines Access’s December 31, 2007 audited consolidated balance sheet with Somanta’s January 4, 2008 unaudited consolidated balance sheet. The unaudited pro forma condensed combined statement of operations gives pro forma effect to the merger as if it had been completed on January 1, 2007 and combines Access’ audited consolidated statement of operations for the year ended December 31, 2007, with Somanta’s unaudited consolidated statement of operations for the nine months ended October 31, 2007.

The pro forma adjustments are based upon available information and certain assumptions that Access believes are reasonable under the circumstances.

Total consideration paid in connection with the acquisition included:

- Approximately 1.5 million shares of Access common stock was issued to the common and preferred shareholders of Somanta as consideration having a value of approximately \$4,650,000 (the value was calculated using Access’ stock price on January 4, 2008 times the shares issued);
- exchange all outstanding warrants for Somanta common stock for warrants to purchase 191,991 shares of Access common stock at exercise prices ranging between \$18.55 and \$69.57 per share. The warrants were valued at approximately \$281,000. All of the warrants are exercisable immediately and expire approximately four years from date of issue. The weighted average fair value of the warrants was \$1.46 per share on the date of the grant using the Black-Scholes pricing model with the following assumptions: expected dividend yield 0.0%, risk-free interest rate 3.26%, expected volatility 114% and an expected term of approximately 4 years;
- an aggregate of \$475,000 in direct transaction costs; and
- cancelled receivable from Somanta of \$931,000.

Approximately \$8,879,000 of the purchase price represents the estimated fair value of the acquired in-process research and development projects that have no alternative future use. Accordingly this amount was immediately expensed and for the purposes of this pro forma is included in additional paid-in capital.

The following table summarizes the initial fair values of the assets acquired and liabilities assumed at the date of the acquisition (in thousands) based on a preliminary valuation. Subsequent adjustments may be recorded upon the completion of the valuation and the final determination of the purchase price allocation.

Cash	\$	1
Prepaid expenses		25
Office equipment, net		14
Accounts payable		(2,582)
In-process research & development		<u>8,879</u>
		\$6,337

These unaudited pro forma condensed combined financial statements should be read in conjunction with the historical consolidated financial statements and related notes contained in the annual, quarterly and other reports filed by Access and Somanta with the Securities and Exchange Commission.

Pro Forma Condensed Combined Balance Sheet
As of December 31, 2007
(Unaudited)

Historical

	Access	Somanta	Pro Forma Adjustments		Pro Forma Combined
ASSETS					
Current assets					
Cash and cash equivalents	\$ 159,000	\$ 2,000			\$ 161,000
Short term investments, at cost	6,762,000				6,762,000
Receivables	35,000				35,000
Receivables from Somanta	931,000		(931,000)	(d)	-
Prepaid expenses and other current expenses	410,000	25,000	(410,000)	(c)	25,000
Total current assets	8,297,000	27,000			6,983,000
Property and equipment, net	130,000	14,000			144,000
Patents net	710,000				710,000
Other assets	12,000				12,000
Total assets	\$ 9,149,000	\$ 41,000			\$ 7,849,000
LIABILITIES AND STOCKHOLDERS' DEFICIT					
Current liabilities					
Accounts payable and accrued expenses	\$ 1,796,000	\$ 2,583,000	(410,000)	(c)	\$ 3,969,000
Accrued interest payable	130,000				130,000
Current portion of deferred revenue	68,000				68,000
Current portion of long-term debt net of discount	64,000	856,000	(856,000)	(d)	64,000
Total current liabilities	2,058,000	3,439,000			4,231,000
Long-term deferred revenue	910,000				910,000
Long-term debt	5,500,000				5,500,000
Total liabilities	8,468,000	3,439,000			10,641,000
Stockholders' equity (deficit)					
Preferred stock	-	-			-
Common stock	36,000	15,000	15,000	(a)	51,000
			(15,000)	(b)	
Additional paid-in capital	116,018,000	7,615,000	4,756,000	(a)	120,774,000
			(7,615,000)	(b)	
Notes receivable from stockholders	(1,045,000)				(1,045,000)
Treasury stock, at cost	(4,000)				(4,000)
Accumulated deficit	(114,324,000)	(11,028,000)	(4,771,000)	(a)	(122,568,000)
			(3,398,000)	(b)	
			11,028,000	(b)	
			(75,000)	(d)	
Total stockholders' equity (deficit)	681,000	(3,398,000)			(2,792,000)
Total liabilities and stockholders' equity (deficit)	\$ 9,149,000	\$ 41,000			\$ 7,849,000

See accompanying Notes to Pro Forma Condensed Combined Balance Sheet

Notes to Pro Forma Condensed Combined Balance Sheet

Note 1: The above statement gives effect to the following pro forma adjustments necessary to reflect the merger of Access and Somanta, as if the transaction had occurred January 1, 2007. Somanta statements used were as of January 4, 2008 (unaudited).

- a) To record the exchange, for accounting purposes, by Somanta shareholders of their preferred and common stock (valued at \$4,650,000) for 1,500,000 shares of Access (or 1,500,000 shares valued at the stock price of \$3.10 per share) and record the exchange of Somanta warrants for Access warrants valued at a fair value of \$281,000. The value placed on the shares was determined based on the Access stock price at January 4, 2008, the date of the acquisition.
- b) To eliminate the shareholders equity section and warrant liabilities of Somanta in connection with the merger and credit the net equity to combined deficit.
- c) Accrual of \$410,000 of legal, accounting and other professional fees relating to the merger.
- d) Eliminate intercompany notes receivable and payable of \$856,000 and other Somanta costs of \$75,000 totaling \$931,000.

After the consummation of the transactions described herein, Access had 100,000,000 common shares authorized, approximately 5,085,023 common shares issued and outstanding, 2,000,000 preferred shares authorized with approximately 3,227.3617 shares of Series A cumulative Convertible Preferred Stock issued and outstanding.

Pro Forma Condensed Combined Statement of Operations
For the Twelve Months Ended December 31, 2007
(Unaudited)

Historical

	Access	Somanta	Pro Forma Combined
Revenues	\$ 57,000	\$ 1,000	\$ 58,000
Expenses			
Research and development	2,602,000	445,000	3,047,000
General and administrative	4,076,000	1,889,000	5,965,000
Depreciation and amortization	279,000	-	279,000
Total expenses	6,957,000	2,334,000	9,791,000
Profit/(Loss) from operations	(6,900,000)	(2,333,000)	(9,233,000)
Interest and miscellaneous income	125,000	(3,000)	122,000
Interest and other expenses	(3,514,000)	(27,000)	(3,541,000)
Loss on extinguishment of debt	(11,628,000)	-	(11,628,000)
Change in fair value of warrant liabilities	-	5,119,000	5,119,000
Currency translation loss	-	(1,000)	(1,000)
Profit/(Loss) before discontinued operations and before income tax benefit	(15,017,000)	5,088,000	(9,929,000)
Income tax benefit	(21,917,000)	2,755,000	(19,162,000)
Profit/(Loss) from continuing operations	61,000	(5,000)	56,000
Less preferred stock dividends	(21,856,000)	2,750,000	(19,106,000)
Loss from continuing operations allocable to common stockholders	(14,908,000)	-	(14,908,000)
Discontinued operations, net of taxes of \$61,000	(36,764,000)	2,750,000	(34,014,000)
Net profit/(loss) allocable to common stockholders	\$ (36,652,000)	\$ 2,750,000	\$ (33,902,000)
Basic and diluted loss per common share			
Profit/(Loss) from continuing operations allocable to all common stockholders	\$ (10.35)	\$ 0.19	\$ (6.73)
Discontinued operations	0.03	-	0.02
Net (loss) allocable to common stockholders	\$ (10.32)	\$ 0.19	\$ (6.71)
Weighted average basic and diluted common shares outstanding	3,552,006	14,630,402	5,052,006

Notes to Pro Forma Condensed Combined Statement of Operations

Note 1: The above statement gives effect to the merger of Access and Somanta, as if the merger had occurred on January 1, 2006. Somanta statements used were for the nine months ended October 31, 2007.

Note 2: The pro forma combined-weighted average number of common outstanding shares is based on the weighted average number of shares of common stock of Access during the period plus those shares to be issued in conjunction with the merger. A reconciliation between Access' historical weighted average shares outstanding and pro forma weighted average shares outstanding and pro forma weighted average shares outstanding is as follows:

Historical	3,552,006
Somanta equivalent shares giving effect to the merger	1,500,000
Total	5,052,006

(c) Exhibits

Number	Title
23.1	Consent of Independent Registered Public Accounting Firm
99.1	Press Release dated January 7, 2008 entitled "Access Pharmaceuticals Closes Acquisition of Somanta Pharmaceuticals"

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

By: Stephen B. Thompson
Vice President, Chief Financial Officer

Date: June 16, 2008

Exhibit Index

Exhibit No.	Description
23.1	Consent of Independent Registered Public Accounting Firm
99.1	Press release issued by Access Pharmaceuticals, Inc. dated January 7, 2008.

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the inclusion in this Form 8-K/A, by reference, of our reports dated June 16, 2006 and June 27, 2007, with respect to our audit of the consolidated balance sheets of Somanta Pharmaceuticals, Inc. and Subsidiaries, as of April 30, 2006 and April 30, 2007, and the related consolidated statements of operations, changes in stockholders' deficit, and cash flows for the years then ended, which appears in the Form 10-KSB filed by Somanta Pharmaceuticals, Inc.

/s/ Stonefield Josephson Inc.

Irvine, California
June 17, 2008

{Logo}

ACCESS NEWS**Contact: Company**

Stephen B. Thompson
Vice President, Chief Financial Officer
Access Pharmaceuticals, Inc.

Investor Relations

Steinberg (media)
Assoc. LLC
(212) 370-4500
(214) 905-

Contact:

Donald C. Weinberger/Alisa
Wolfe Axelrod Weinberger

100

Pharmaceuticals**732-4300****Andrew Hellman, CEOcast, Inc. for Access****(212)****ACCESS PHARMACEUTICALS CLOSES ACQUISITION OF SOMANTA PHARMACEUTICALS****- Acquisition of Four Potent Anti-cancer Products Fills Out Robust Pipeline - -**

DALLAS, TX, January 7, 2008, Access Pharmaceuticals, Inc. (OTC BB: ACCP) announced today that it has closed the acquisition of Somanta Pharmaceuticals, Inc. (OTC BB: SMPM) through the issuance of 1.5 million shares of Access Pharmaceuticals' common stock, as previously announced. Somanta's broad portfolio of drug candidates features four novel anti-cancer compounds in development, each of which acts by a unique mechanism of action and has the potential to target a wide range of different cancer types. The Somanta product candidate portfolio includes Angiolix, a humanized monoclonal antibody with a unique target, Prodrax, a novel prodrug and platform technology that enables compounds to reach the hypoxic region of tumors, Alchemix, a multi-target inhibitor that is specifically designed to be effective against cancer cells resistant to conventional chemotherapy, and sodium phenylbutyrate, an HDAC inhibitor, that is currently in Phase 2 clinical development.

Additionally, it is anticipated that select members of Somanta's management team who have established track records of guiding compounds through the FDA and EMEA approval processes will join the Access team.

"The acquisition of Somanta brings four very exciting product candidates and one platform technology into the Access pipeline, and we look forward to advancing them towards clinical development this year," stated Jeffrey B. Davis, Access' Chairman and CEO. "Together with the ongoing development efforts with ProLindac and the Cobalamin oral insulin programs, we feel that the Somanta product candidates position us very well for the next few years. In addition to internal development of these products, we are actively seeking development and marketing partners for our products, both domestically and overseas."

About Angiolix®: Angiolix is a humanized monoclonal antibody (huMc-3 mAB) that is unique in that its proprietary target is a protein known as lactadherin. Lactadherin is a potent stimulator of angiogenesis, promoting the growth of new blood vessels to support tumor growth. Angiolix, by blocking lactadherin (by inhibiting the binding of Lactadherin to integrin), has the potential to induce programmed cell death, or apoptosis, in blood vessels that support tumors.

-More-

About Prodrax®: Prodrax is a novel prodrug platform technology that enables compounds to remain inert until they reach the hypoxic or low oxygen regions of tumors, where they become toxic and enable effective tumor killing.

About Alchemix®: Alchemix is a chloroethylaminoanthraquinone, a multi-target inhibitor specifically designed to overcome the problem of multi-drug resistance. Pre-clinical studies have been completed, and a Phase I dose-escalating trial is expected to commence in late 2008.

About Phenylbutyrate: Sodium phenylbutyrate (PB), an HDAC inhibitor, has been investigated in multiple Phase 1/2 NIH and clinician-sponsored trials, and is currently approved by the FDA for the treatment of hyperuremia, a pediatric orphan indication. PB has a well known safety profile, and is currently in the Phase 2 development by Access' US partner, Virium Pharmaceuticals, Inc.

About Access: Access Pharmaceuticals, Inc. is a biotechnology company that leverages its proprietary nano-polymer chemistry expertise to develop proprietary products. Access' products include ProLindac™, a novel DACH platinum drug that is currently in Phase 2 clinical testing of patients with ovarian cancer and MuGard™ for the management of patients with mucositis. The Company also has other advanced drug delivery technologies including Cobalamin™-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at <http://www.accesspharma.com>.

About ProLindac™: ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of \$2 billion.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and the product candidates acquired in the Somanta transaction, the execution of license agreements in the future and our ability to execute development agreements in the future. These statements are subject to numerous risks, including but not limited to Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' and Somanta's Annual Reports on Form 10-KSB and other reports filed by Access and Somanta with the Securities and Exchange Commission.

###